OmniComm Systems, Inc.
Fort Lauderdale, FL, March 3, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, today announced the signing of a multi-year agreement with ICON for OmniComm Systems’ market leading TrialOne technology for Phase I clinic automation. ICON is one of the world’s largest contract research organizations (CROs) with around 10,600 employees in 38 countries. ICON provides drug development solutions and services on a global basis to the pharmaceutical, biotechnology, and medical device industries supporting all stages of the clinical development process.
After a thorough evaluation of commercially available Phase I software, ICON selected OmniComm’s TrialOne suite. TrialOne will enable ICON to further automate their data collection; standardize recruiting; collect study data; track samples; and ensure regulatory compliance within their Phase I clinic. Moving to a complete electronic source record was a critical factor in ICON’s selection of TrialOne. TrialOne provides ICON with advanced Phase I electronic data capture and clinic operations automation technology. TrialOne’s purpose-built eSource capability ensures regulatory compliance with FDA’s guidance on electronic source data in clinical investigations. Also important in ICON’s selection of TrialOne was the need for a comprehensive software solution that integrates with bedside patient monitoring, telemetry devices, and the ability to send electrocardiography (ECG) orders to devices.
“This selection by ICON marks the fourth significant win for us with major CROs in the last six months, further bolstering our position as the market leader in Phase I clinic automation,” said Stephen Johnson, president and chief operating officer at OmniComm. “Establishing ourselves as the dominant player in the Phase I space has been a major priority for us and it is rewarding to see our hard work paying off. OmniComm will continue to put significant development efforts into our product line to support this rapidly growing part of our business.”
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 83 locations in 38 countries and has approximately 10,600 employees. Further information is available at www.iconplc.com.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
OmniComm Systems, Inc.